To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Cisbio Bioassays Honored with the 2009 Frost & Sullivan
Read time: 1 minute
Cisbio Bioassays, member of IBA group and global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, today announced that it was the recipient of the 2009 Frost & Sullivan North America Technology Innovation of the Year Award for Molecular Bioassays. The award recognizes Cisbio Bioassays’ development of Tag-lite™, its paradigm shifting technology for cell surface receptor investigation, and Tag-lite™’s impact on G-protein coupled receptor (GPCR) drug discovery research.
“We are honored to be recognized by Frost & Sullivan as a research-driven company with outstanding technology,” said François Degorce, head of marketing at Cisbio Bioassays. “Throughout Tag-lite™’s development, we were confident that it would be a revolutionary breakthrough in GPCR studies from an R&D perspective, and we continue to build this platform from other research angles. For over a decade, Cisbio Bioassays has been committed to R&D innovation and privileged partnerships with research institutions such as IGF in Montpellier, France, which specializes in GPCR studies and was instrumental in validating Tag-lite™.”
Tag-lite™, combining both HTRF® and SNAP-tag™ technologies, is a homogeneous, non-radioactive and costeffective alternative for the study of cell surface receptor dimerization and ligand binding, two important investigation avenues in GPCR drug discovery research. The platform was developed by Cisbio Bioassays’ as part of its ongoing commitment to improve existing technologies, streamline protocols, and eliminate the need for radioactive assays.
Tag-lite™ is part of Cisbio Bioassays’ HTRF® Terbium-based GPCR platform, which already includes second messenger assay kits for the functional assessment of GPCR activity. It is used by pharmaceutical and biotechnology researchers worldwide for its ease of assay development, robustness, and assay sensitivity.
“Given the extremely high therapeutic relevance of GPCRs, the development of the Tag-lite™ technology by Cisbio Bioassays assumes even greater significance in the context of drug discovery and pharmaceutical development,” explained Dr. Sudeep Basu, senior analyst, drug discovery technologies & clinical diagnostics, Frost & Sullivan. “With its complete suites of products and services including plasmids, cell lines and ligands, Cisbio Bioassays is extremely well positioned to serve the longstanding unmet needs of GPCR characterization.”
Frost & Sullivan’s Technology Innovation Award is bestowed upon a company that has carried out new research resulting in an innovation that will bring significant contributions to the industry in terms of adoption, change, and competitive posture. The award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.
“We are honored to be recognized by Frost & Sullivan as a research-driven company with outstanding technology,” said François Degorce, head of marketing at Cisbio Bioassays. “Throughout Tag-lite™’s development, we were confident that it would be a revolutionary breakthrough in GPCR studies from an R&D perspective, and we continue to build this platform from other research angles. For over a decade, Cisbio Bioassays has been committed to R&D innovation and privileged partnerships with research institutions such as IGF in Montpellier, France, which specializes in GPCR studies and was instrumental in validating Tag-lite™.”
Tag-lite™, combining both HTRF® and SNAP-tag™ technologies, is a homogeneous, non-radioactive and costeffective alternative for the study of cell surface receptor dimerization and ligand binding, two important investigation avenues in GPCR drug discovery research. The platform was developed by Cisbio Bioassays’ as part of its ongoing commitment to improve existing technologies, streamline protocols, and eliminate the need for radioactive assays.
Tag-lite™ is part of Cisbio Bioassays’ HTRF® Terbium-based GPCR platform, which already includes second messenger assay kits for the functional assessment of GPCR activity. It is used by pharmaceutical and biotechnology researchers worldwide for its ease of assay development, robustness, and assay sensitivity.
“Given the extremely high therapeutic relevance of GPCRs, the development of the Tag-lite™ technology by Cisbio Bioassays assumes even greater significance in the context of drug discovery and pharmaceutical development,” explained Dr. Sudeep Basu, senior analyst, drug discovery technologies & clinical diagnostics, Frost & Sullivan. “With its complete suites of products and services including plasmids, cell lines and ligands, Cisbio Bioassays is extremely well positioned to serve the longstanding unmet needs of GPCR characterization.”
Frost & Sullivan’s Technology Innovation Award is bestowed upon a company that has carried out new research resulting in an innovation that will bring significant contributions to the industry in terms of adoption, change, and competitive posture. The award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.
